Equities

ADMA Biologics Inc

ADMA:NMQ

ADMA Biologics Inc

Actions
  • Price (USD)21.78
  • Today's Change-0.70 / -3.11%
  • Shares traded4.18m
  • 1 Year change+477.72%
  • Beta0.7345
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments518751
Total Receivables, Net271629
Total Inventory173163125
Prepaid expenses5.335.104.34
Other current assets, total------
Total current assets257270209
Property, plant & equipment, net636958
Goodwill, net3.533.533.53
Intangibles, net0.501.011.73
Long term investments------
Note receivable - long term------
Other long term assets4.674.774.07
Total assets329348276
LIABILITIES
Accounts payable161312
Accrued expenses312417
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total3.091.941.15
Total current liabilities503930
Total long term debt13114395
Total debt13114395
Deferred income tax------
Minority interest------
Other liabilities, total14149.84
Total liabilities194196135
SHAREHOLDERS EQUITY
Common stock0.020.020.02
Additional paid-in capital641630553
Retained earnings (accumulated deficit)(506)(478)(412)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity135152141
Total liabilities & shareholders' equity329348276
Total common shares outstanding226222196
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.